What is the catalog number for μ-TRTX-Hd1a?

The catalog number for μ-TRTX-Hd1a is HY-P5790.

What sizes are available for μ-TRTX-Hd1a?

μ-TRTX-Hd1a is available in the following size(s): 1 Each.

Is μ-TRTX-Hd1a in stock?

μ-TRTX-Hd1a is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures μ-TRTX-Hd1a?

μ-TRTX-Hd1a is manufactured by QuantiMol.

What is the estimated delivery time for μ-TRTX-Hd1a?

Estimated delivery time for μ-TRTX-Hd1a is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for μ-TRTX-Hd1a?

The safety data sheet for μ-TRTX-Hd1a is available here: http://file.medchemexpress.com/batch_PDF/HY-P5790/.

μ-TRTX-Hd1a

μ-TRTX-Hd1a, a spider venom, is a selective NaV 1.7 inhibitor. μ-TRTX-Hd1a is a gating modifier that inhibits human NaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II[1].

Product Specifications

UNSPSC

12352209

Target

Sodium Channel

Type

Peptides

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/μ-trtx-hd1a.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@@H](CSSC[C@@H](C(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@H]1C)=O)=O)=O)=O)=O)=O)NC2=O)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC3=CC=CC=C3)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CO)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCCN)C(N[C@@H](CC4=CNC=N4)C(N[C@@H](CCCCN)C(N[C@H]5CC6=CNC7=CC=CC=C67)=O)=O)=O)=O)=O)=O)NC1=O)C(N[C@@H](CC(N)=O)C(N8[C@@H](CCC8)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@H]2CSSC[C@@H](C(N[C@@H](CCCCN)C(N[C@@H](CC9=CC=C(C=C9)O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)NC5=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N

Molecular Formula

C160H246N46O51S6

Molecular Weight

3822.33

References & Citations

[1]Julie K Klint, et al. Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach. Br J Pharmacol. 2015 May;172 (10) :2445-58.